TruTechnologies Secures Significant Growth Investment From LLR Partners
TruTechnologies aims to enhance workflow efficiency for research sites while enabling real-time visibility and interventions for pharmaceutical companies and clinical research organizations. Its flagship solution, TruLab ®, is a first-of-its-kind mobile-enabled offering for protocol-driven clinical trial oversight, biological sample management and tracking and risk-based monitoring.
'TruTechnologies was founded to solve the ongoing pain point in clinical research of managing biological samples with accuracy, efficiency and compliance,' said Scott Ogle, Co-Founder and CEO of TruTechnologies. 'LLR understands our mission, our customers and our industry. We are excited to partner with LLR as we scale to deliver more value to pharmaceutical companies, clinical research organizations and research sites around the world.'
Building on TruLab, TruTechnologies has launched two complementary solutions: TruDose ™, which provides dosing compliance and deviation monitoring, and TruScreen ™, which enables real-time visibility to trial participant screening visits and associated outcomes.
"After 25 years in drug development, I've seen firsthand how lack of visibility into study conduct significantly impacts clinical trial outcomes," said Rick Graham, PhD, Co-Founder and Chairman of TruTechnologies. 'That's why I'm so proud of what we've built - a solution that finally brings transparency, accountability and oversight to one of the most overlooked aspects of clinical trial execution."
LLR's investment in TruTechnologies builds on its history of partnering with companies driving efficiency and innovation across life sciences and healthcare.
'TruTechnologies has pioneered a differentiated solution in a critical but historically underserved area of clinical trials,' said Zack Sigal, Partner at LLR Partners. William Sadock, Vice President at LLR Partners, added, 'The market TruTechnologies serves is driven by the increasing complexity of clinical trials and demand for more precise, real-time oversight and interventions across the research ecosystem. We are excited to partner with TruTechnologies as they continue to support more clinical teams with real-time insights.'
BofA Securities, Inc. served as the exclusive financial advisor to TruTechnologies in this transaction. Wachtell, Lipton, Rosen & Katz served as legal advisor to TruTechnologies. DLA Piper served as legal advisor to LLR Partners.
About TruTechnologies
Founded in 2018, TruTechnologies is the leading provider of real-time clinical trial oversight, focused on enabling timely, high-quality data and mitigating risks in drug development. The company partners with six top 20 pharmaceutical companies and numerous biotechnology firms to accelerate patient screening and enrollment, drive protocol adherence, and correct deviations. Learn more at TruTechnologies.io and follow on LinkedIn.
About LLR Partners
LLR Partners is a lower middle market private equity firm investing in technology and healthcare businesses. We collaborate with our portfolio companies to define high-impact growth initiatives, turn them into action and help create long-term value. Founded in 1999 and with more than $7 billion raised across seven funds, LLR is a flexible provider of equity capital for growth, recapitalization and buyouts. Learn more at www.llrpartners.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
2 hours ago
- Business Wire
VIQ Solutions Posts Fifth Straight Positive Adjusted EBITDA Quarter
MISSISSAUGA, Ontario--(BUSINESS WIRE)--VIQ Solutions Inc. ('VIQ' or 'the Company') (TSX: VQS), a global leader in AI-powered digital documentation, today announced financial results for the three and six months ended June 30, 2025. The Company reported continued margin expansion, its fifth consecutive quarter of positive Adjusted EBITDA, and secured its largest SaaS deployment to date, reinforcing its leadership in secure, evidence-based transcription for regulated sectors. Second Quarter 2025 Financial Highlights Revenue: $10.4 million, decrease of 10%, from the same period in the prior year, reflecting the timing of customer volumes and market conditions. Gross Margin: 48%, up from 45.5% from the same period in the prior year, driven by automation and productivity gains. Adjusted EBITDA: $1 million, increase of $0.2 million or 24% from the same period in the prior year, marking the fifth consecutive quarter of positive results. Adjusted Operating Loss: $0.8 million, compared to $0.6 million from the same period in the prior year. First Half 2025 Financial Highlights Revenue: $20 million, decrease of 7%, from the same period in the prior year, reflecting the timing of customer volumes and market conditions. Gross Margin: Nearly 50%, up from 44.9% from the same period in the prior year, driven by automation and productivity gains. Adjusted EBITDA: $1.8 million, increase of $1.1 million or 164% from the same period in the prior year, reflecting sustained cost discipline and efficiency gains. Adjusted Operating Loss: $1.5 million, an improvement of $0.9 million. Strategic and Operational Highlights Landmark SaaS Court Deployment: In July 2025, VIQ secured its largest SaaS engagement to date, implementing NetScribe® across 9 judicial districts and 22 counties in the U.S. Midwest. This milestone accelerates VIQ's transition to a higher-margin, subscription-based revenue model. AI-Driven Workflow Automation: The deployment integrates NetScribe®, aiAssist™, Advanced Formatter, supporting internally produced transcription with scalability and optional add-ons including domain-specific language models, advanced post-processing rules, multilingual support, and automated summarization. First Half 2025 Organic Bookings Momentum: VIQ secured $1.9 million of new bookings during first half of 2025, supporting ongoing gross margin expansion and strengthening long-term free cash flow prospects. Management Commentary 'In the first half of 2025, VIQ delivered 164% growth in Adjusted EBITDA, expanded gross margins to nearly 50%, and achieved our fifth consecutive quarter of positive EBITDA,' said Alexie Edwards, CFO of VIQ Solutions. 'While we reported a net loss, this includes approximately $2.0 million in non-cash expenses, such as depreciation, amortization, and stock-based compensation, with $1.1 million recorded in Q2. These charges impact earnings per share but do not affect our cash flow.' 'With our largest SaaS deployment now in motion, increased bookings, and a clear focus on strengthening the balance sheet and reducing debt, we are expanding our financial flexibility to reinvest in growth. Our AI-driven platform and automation strategy continue to fuel stronger margins and sustained EBITDA gains, laying the foundation for long-term growth and value creation.' A copy of the Company's unaudited financial statements and accompanying MD&A for the three and six months ended June 30, 2025 (collectively, the 'Financial Information') will be available under the Company's profile on SEDAR+ at Conference Call Details VIQ will host a conference call and webcast to discuss Financial Information on August 14, 2025, at 11:00 a.m. (Eastern time). The call will consist of updates by Alexie Edwards, VIQ's Chief Financial Officer followed by a question-and-answer period. Investors may access a live webcast of the call on the Company's website at or by dialing 1-888-440-4052 (North America toll-free) or +1-646-960-0827 (international) to be connected to the call by an operator using conference ID number 4983233. Participants should dial at least 10 minutes before the call starts. A replay of the webcast will be available on the Company's website through the same link approximately one hour after the conference call concludes. For more information about VIQ, please visit About VIQ Solutions VIQ Solutions is a global provider of secure, AI-driven, digital voice and video capture technology and transcription services. VIQ offers a seamless, comprehensive solution suite that delivers intelligent automation, enhanced with human review, to drive transformation in the way content is captured, secured, and repurposed into actionable information. The cyber-secure, AI technology and services platform are implemented in the most rigid security environments including criminal justice, legal, insurance, government, corporate finance, media, and transcription service provider markets, enabling them to improve the quality and accessibility of evidence, to easily identify predictive insights and to achieve digital transformation faster and at a lower cost. Forward-looking Statements Certain statements included in this press release constitute forward-looking statements or forward-looking information (collectively, 'forward-looking statements') under applicable securities legislation. Such forward-looking statements or information are provided for the purpose of providing information about management's current expectations and plans relating to the future. Readers are cautioned that reliance on such information may not be appropriate for other purposes. Forward-looking statements typically contain statements with words such as 'anticipate', 'believe', 'expect', 'plan', 'intend', 'estimate', 'propose', 'project' or similar words, including negatives thereof, suggesting future outcomes or that certain events or conditions 'may' or 'will' occur. These statements are only predictions. Forward-looking statements in this press release include but are not limited to statements with respect to the Company's ability to accelerate automation, optimize costs, and improve scalability in the future, expected margin improvement, the Company's focus and its priorities, the filing of the Financial Information on SEDAR+ and the conference call to discuss the Company's financial results. Forward-looking statements are based on several factors and assumptions which have been used to develop such statements, but which may prove to be incorrect. Although VIQ believes that the expectations reflected in such forward-looking statements are reasonable, undue reliance should not be placed on forward-looking statements because VIQ can give no assurance that such expectations will prove to be correct. In addition to other factors and assumptions which may be identified in this press release, assumptions have been made regarding, among other things, recent initiatives, cost savings from workforce and product optimization, cost reductions from the Company's workflow solutions and that sales and prospects may increase revenue. Readers are cautioned that the foregoing list is not exhaustive of all factors and assumptions that have been used. Forward-looking statements are necessarily based on a number of opinions, assumptions and estimates that while considered reasonable by the Company as of the date of this press release, are subject to known and unknown risks, uncertainties, assumptions, and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking statements, including but not limited to the factors described in greater detail in the 'Risk Factors' section of the Company's annual information form and in the Company's other materials filed with the Canadian securities regulatory authorities. These factors are not intended to represent a complete list of the factors that could affect the Company; however, these factors should be considered carefully. Such estimates and assumptions may prove to be incorrect or overstated. The forward-looking statements contained in this press release are made as of the date of this press release and the Company expressly disclaims any obligations to update or alter such statements, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law. Non-IFRS Measures The Company prepares its financial statements in accordance with IFRS. Non-IFRS measures are provided by management to provide additional insight into our performance and financial condition. VIQ believes non-IFRS measures are an important part of the financial reporting process and are useful in communicating information that complements and supplements the consolidated financial statements. Adjusted EBITDA and adjusted operating loss are not measures recognized by IFRS and do not have a standardized meanings prescribed by IFRS. Therefore, Adjusted EBITDA and adjusted operating loss may not be comparable to similar measures presented by other issuers. Investors are cautioned that Adjusted EBITDA and adjusted operating loss should not be construed as alternatives to net income (loss) as determined in accordance with IFRS. For a reconciliation of net income (loss) to Adjusted EBITDA and adjusted operating loss please see the Company's MD&A for three and six months ended June 30, 2025. To evaluate the Company's operating performance as a complement to results provided in accordance with IFRS, the term 'Adjusted EBITDA' refers to net income (loss) before adjusting earnings for stock-based compensation, depreciation, amortization, interest expense, accretion, and other financing expense, (gain) loss on revaluation of options, (gain) loss on revaluation of restricted share units, gain (loss) on revaluation of derivative warrant liability, restructuring costs, strategic review costs, loss on modification of debt, impairment of property and equipment, impairment of goodwill and intangibles, other expense (income), foreign exchange (gain) loss, current and deferred income tax expense. We believe that the items excluded from Adjusted EBITDA are not connected to and do not represent the operating performance of the Company. We believe that Adjusted EBITDA is useful supplemental information as it provides an indication of the results generated by the Company's main business activities prior to taking into consideration how those activities are financed and taxed as well as expenses related to stock-based compensation, depreciation, amortization, impairment of goodwill and intangibles, loss on modification or extinguishment of debt, other expense (income), and foreign exchange (gain) loss. Accordingly, we believe that this measure may also be useful to investors in enhancing their understanding of the Company's operating performance. The term 'adjusted operating loss' refers to net income (loss) excluding the impact of strategic review costs. Management believes it is appropriate to adjust for this item because strategic review costs do not relate to operating activities of the Company and is useful supplemental information as it provides an indication of the results generated by the Company's main business activities. The presentation of this measure enables investors and analysts to better understand the underlying performance of our business activities. We calculate 'bookings' for a given period as the estimated contract value (for services tied to volume) of our recurring client contracts entered into during the period from (i) new clients and (ii) net upgrades by existing clients within the same workload, plus the actual (not annualized) estimated value of professional services consulting, advisory or project-based orders received, software licenses, subscriptions, SaaS, and hardware during the period. Trademarks This press release includes trademarks, such as 'NetScribe', which are protected under applicable intellectual property laws and are the property of VIQ. Solely for convenience, our trademarks referred to in this press release may appear without the ® or TM symbol, but such references are not intended to indicate, in any way, that we will not assert our rights to these trademarks, trade names, and services marks to the fullest extent under applicable law. Trademarks that may be used in this press release, other than those that belong to VIQ, are the property of their respective owners. VIQ Solutions Inc. Interim Condensed Consolidated Statements of Loss and Comprehensive Loss (Expressed in US dollars, unaudited) Three months ended June 30, Six months ended June 30, 2025 2024 2025 2024 Revenue $ 10,445,488 $ 11,575,614 $ 20,024,513 $ 21,497,287 Cost of sales 5,436,220 6,312,797 10,040,105 11,841,912 Gross profit 5,009,268 5,262,817 9,984,408 9,655,375 Expenses Selling and administrative expenses 3,866,110 4,328,687 7,676,752 8,639,461 Research and development expenses 179,957 155,416 320,476 320,526 Stock-based compensation 292,682 111,283 291,865 139,816 Gain on revaluation of RSUs (21,482 ) (18,534 ) (19,553 ) (47,311 ) Loss (gain) on revaluation of the derivative Warrant liability 8,260 7,479 1,238 (49,686 ) Foreign exchange gain (354,295 ) (590,719 ) (438,327 ) (487,886 ) Depreciation 175,864 194,237 340,547 389,221 Amortization 658,581 813,889 1,366,158 1,620,346 Interest expense 439,704 405,965 928,326 794,889 Accretion and other financing costs 456,029 425,216 875,059 752,094 Restructuring costs (recovery) 37,349 5,874 36,066 (3,820 ) Strategic review costs 119,124 – 1,294,726 – Other income (1,911 ) (10,208 ) (8,118 ) (21,413 ) Total expenses 5,855,972 5,828,585 12,665,215 12,046,237 Current income tax expense 52,654 6,063 86,933 21,107 Income tax expense 52,654 6,063 86,933 21,107 Net loss for the period $ (899,358 ) $ (571,831 ) $ (2,767,740 ) $ (2,411,969 ) Exchange (loss) gain on translation of foreign operations 16,115 (483,076 ) 15,027 (795,107 ) Comprehensive loss for the period $ (883,243 ) $ (1,054,907 ) $ (2,752,713 ) $ (3,207,076 ) Net loss per share Basic (0.02 ) (0.01 ) (0.05 ) (0.05 ) Diluted (0.02 ) (0.01 ) (0.05 ) (0.05 ) Weighted average number of common shares outstanding – basic 52,563,142 51,348,578 52,449,214 48,065,488 Weighted average number of common shares outstanding – diluted 52,563,142 51,348,578 52,449,214 48,065,488 Expand The following is a reconciliation of Net Loss to Adjusted EBITDA, the most directly comparable IFRS measure for the three and six months ended June 30, 2025, and 2024: The following is a reconciliation of Net Loss to Adjusted operating loss, the most directly comparable IFRS measure for the three and six months ended June 30, 2025, and 2024:
Business Wire
4 hours ago
- Business Wire
Amber Specialty Pharmacy Begins Dispensing Newly Approved BRINSUPRI™ (brensocatib) for Non-Cystic Fibrosisbronchiectasis (NCFB)
OMAHA, Neb.--(BUSINESS WIRE)--Amber Specialty Pharmacy, a pioneer in specialty pharmacy for more than 25 years, today announced it is now dispensing BRINSUPRI™ (brensocatib) following the medication's U.S. Food and Drug Administration (FDA) approval as the first treatment specifically indicated to reduce pulmonary exacerbations in adults and adolescents with non-cystic fibrosis bronchiectasis, a chronic neutrophil-mediated airway disease. 'Our nationally recognized clinical program is ready to ensure rapid access, personalized counseling, and comprehensive reimbursement support for every patient who needs it,' said Kristin Williams, president of Amber Specialty Pharmacy. Amber Specialty Pharmacy streamlines the treatment process for both patients and referring providers by offering the following support services: Nationwide dispensing through its URAC and ACHC-accredited network 24/7 clinical support and adherence counseling from specialty-licensed pharmacists End-to-end benefits investigation, prior authorization and financial assistance coordination Healthcare providers can initiate BRINSUPRI referrals by calling (888) 370-1724 or visiting to download electronic referral forms. About Amber Specialty Pharmacy Amber Specialty Pharmacy is a pioneer in the specialty pharmacy industry, with more than 25 years of experience in providing specialized care for patients with chronic and complex medical conditions. With a focus on personalized support and quality clinical care, Amber Specialty Pharmacy serves patients across the United States. The pharmacy is accredited by both the Utilization Review Accreditation Commission (URAC) and the Accreditation Commission for Health Care (ACHC). Amber Specialty Pharmacy is headquartered in Omaha, Nebraska. To learn more, visit
Business Wire
5 hours ago
- Business Wire
UNIFI ®, Makers of REPREVE ®, Schedules Fourth Quarter Fiscal 2025 Earnings Conference Call
GREENSBORO, N.C.--(BUSINESS WIRE)--Unifi, Inc. (NYSE: UFI), (together with its consolidated subsidiaries, 'UNIFI'), the makers of REPREVE ® and one of the world's leading innovators in recycled and synthetic yarns, will host a conference call at 9:00 a.m., Eastern Time, on Thursday, August 21, 2025, to discuss its fourth quarter fiscal 2025 financial results. The fourth quarter fiscal 2025 financial results and supporting materials will be available after the close of market trading on Wednesday, August 20, 2025, on the Company's website at The conference call can be accessed approximately 10 minutes prior to the beginning of the call by dialing (646) 307-1963 (Domestic) or (800) 715-9871 (International) and, when prompted, providing conference ID number 7913423. There will also be a live audio webcast of the call, which can be accessed on the Company's website at A replay of the conference call will be available approximately two hours following the call through Thursday, August 28, 2025, and can be accessed via the Company's website at In addition, presentation slides will be available on the Company's website for 12 months following the call. About UNIFI, Inc. UNIFI, Inc. (NYSE: UFI) is a global leader in fiber science and sustainable synthetic textiles. Using proprietary recycling technology, UNIFI is a pioneer in scaling the transformation of post-industrial and post-consumer waste into sustainable products. Through REPREVE ®, the world's leading brand of traceable, recycled fiber and resin, UNIFI is changing the way industries think about the materials they use – and reuse. A vertically-integrated manufacturer, the company has direct operations in the United States, Colombia, El Salvador, and Brazil, and sales offices all over the world. UNIFI envisions a future where circular and sustainable solutions are the only choice. For more information about UNIFI, visit Made by UNIFI, Inc. (NYSE: UFI), REPREVE® is the global leader in recycled performance fibers and resins. Using proprietary recycling technology, REPREVE leverages multiple waste sources, including single-use plastic bottles, ocean-bound plastic, textile waste, and recycled yarn. REPREVE has transformed more than 40 billion plastic bottles into recycled fiber, powering globally scalable products for world-leading brands. Made traceable with FiberPrint® technology and certified by U-Trust®, REPREVE spans sports apparel, fashion, home, automotive, construction, transport, military, medical and packaged goods. For more information about REPREVE, visit
